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Drug-eluting stents (DES) have become the primary treat-
ment modality for patients with coronary artery disease requir-
ing revascularization (1). The attractiveness of DES involves
their dramatic ability to inhibit neointimal proliferation leading
to a marked reduction in the clinical need for reinterventions
(2). Since their first clinical use a decade ago, DES have
xperienced a major evolution. Recent generation devices have
mproved platforms facilitating their unrestricted use as a
orkhorse strategy in increasingly challenging anatomic sce-
arios. In addition, they incorporate advanced polymers with
he aim of avoiding any potential untoward stimulus for late
nflammatory reactions. Finally, currently available DES elute
ighly attractive drugs (2–4). Notwithstanding the value of
See page 1844
these advances, a critical question remains unsolved, namely
whether the potent antiproliferative properties of DES may be
dissociated from a delayed vessel healing response (5). Indeed,
elayed endothelization has been considered as the unavoid-
ble price to pay to benefit from their unique antirestenotic
fficacy (5). Accordingly, prolonged dual antiplatelet therapy is
ecommended after DES implantation, as a safety net, during
he period required for complete vascular wall restoration.
evertheless, despite all technological advancements and im-
rovements in concomitant medical therapy, the risk of very
ate DES thrombosis remains an issue of special concern (6).
ortunately, this feared complication is very rare, even in the
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contents of this paper to disclose.eal-world clinical setting, and recent registry data suggest that
ts incidence may be declining (7,8).
Recent head-to-head randomized comparisons of first-
eneration DES with newer generation devices strongly sug-
est that new DES appear to be not only more effective but
lso safer (2–4). Surprisingly, however, in most of these studies
nly paclitaxel-eluting stents (PES) have been used as a
omparator in the control arm. This action is worrisome
ecause classical reports and meta-analysis suggest that
irolimus-eluting stents (SES) are actually more effective and
afer than contemporary PES (9). From this perspective, the
eal clinical value of second-generation DES remains unset-
led. Likewise, comparisons of current results with historical
eries are likely flawed by various chronological biases. There-
ore, it remains possible that the improved current results may
ctually be secondary to a longer experience with the use of
ES, resulting in better patient selection, improved deploy-
ent strategies, superior antithrombotic regimens, and closer
linical surveillance, rather than to superior performance of the
ew DES (2,7,8).
In this issue of the Journal, Park et al. (10) present the results
f the first head-to-head randomized comparison of
verolimus-eluting stents (EES) with SES in relatively unse-
ected patients. This trial would be considered by many as
nother second- versus first-generation DES-to-DES contest.
otably, however, compared with SES, EES were unable to
rovide superior results in any of the pre-established clinical or
ngiographic outcome measures (10). Many clinicians and
esearches would consider these results to be puzzling or even
isappointing.
Are second-generation DES superior to first-generation
ES? Is this classification meaningful or rather over-simplistic
nd arbitrary? Are all limus DES equally safe and effective? Are
e pushing the envelope too early or too far? Are we just flying
oo high?
resent study. The EXCELLENT (Efficacy of Xience/
romus Versus Cypher to Reduce Late Loss After Stenting)
rial (10) included 1,443 patients randomized (3:1) to receive
ES (n  1,079; 1,459 lesions) or SES (364 patients; 468
esions) in 19 Korean centers. The trial had a noninferiority
esign and was powered for its primary angiographic endpoint.
ased on previous studies, a late loss of 0.2 mm was anticipated
or both arms, and a noninferiority margin of 0.1 mm was
redefined. The primary endpoint, the in-segment late loss at
-month angiographic follow-up, was similar in both arms
EES 0.11  0.38; SES 0.06  0.36 mm), with the upper
onfidence interval (0.096 mm) just falling within the pre-
pecified noninferiority margin (p for noninferiority 0.0382).
mportantly, however, late angiographic follow-up was only
btained in 67% of patients. This finding is lower than
xpected for a randomized trial with an angiographic primary
ndpoint (the trial design anticipated 80% of angiographic
ollow-up) and, actually, might jeopardize the value of the
elected noninferiority margin because dropouts may dilute
otential differences between treatments.
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particular methodological issues regarding design, conduct,
analysis, and interpretation (11). In these studies, the null and
alternative hypotheses are reversed and, therefore, a type II
error is the erroneous rejection of a truly noninferior treatment.
Furthermore, the selected noninferiority margin should be the
smallest value that would be considered a “clinically relevant”
effect. Finally, in noninferiority trials, intention-to-treat anal-
yses may increase the risk of falsely claiming noninferiority
(type I error). Therefore, in these trials, “non–intention-to-
treat” analyses are particularly important as a protection from
this problem. The EXCELLENT investigators selected the
per-protocol analysis for the primary angiographic endpoint. In
this regard, although probably not affecting the main study
findings, the trend for a higher device success rate in the EES
arm (10)—possibly resulting from its superior deliverability—
should be also kept in mind.
Both groups were well balanced for baseline characteristics,
although a higher number of stents was required in the EES
arm (10). The investigators suggest that the trial was designed
to reflect “real-life” clinical practice. From the clinical stand-
point, many patients with unstable disease were enrolled and
only patients with cardiogenic shock, recent myocardial infarc-
tion, and “severe” left ventricular dysfunction/renal failure were
excluded. From the anatomic perspective, vessel size, lesion
length, and the presence of multiple lesions were not exclusion
criteria although, again, highly complex anatomic settings were
not included. Although these criteria are rather inclusive for a
randomized trial, caution is required before extrapolating the
study findings to truly unselected real-world patients seen in
daily practice. Likewise, nearly one-half of the patients (44%)
received intravascular ultrasound–guided stenting. This is not
standard practice in most institutions and should also be
considered before current results are generalized to settings in
which angiography alone is used to optimize procedural results.
Multivessel intervention was also allowed in this trial (10).
Considering that multiple lesions could be targeted with the
allocated DES, generalized estimating equations were required
to statistically account for potential clustering effects. Notably,
when all lesions eventually treated were compared (i.e., not
only the “index” lesion selected for the primary endpoint), the
in-segment late loss (0.10  0.36 mm vs. 0.05  0.34 mm)
tended to be higher (p  0.05) after EES (10).
Secondary clinical endpoints, including death, target lesion/
target vessel failure, myocardial infarction, and stent thrombo-
sis, were equivalent in both arms. Although event rates were
similar, “effectiveness” outcome measures were numerically
higher whereas those related to “safety” were numerically lower
after EES. As nicely acknowledged, however, the study was
largely underpowered to detect differences in major clinical
endpoints. From these unstable trends, the authors elegantly
dare to suggest that EES might be safer than SES although
perhaps slightly less effective. It was speculated that the latter
might be a result of EES offering a potentially less effective
drug at a lower concentration compared with SES (10,12). In
addition, the EXCELLENT trial had a 2 2 factorial designand concomitantly evaluated the effect of the duration
(6 months vs. 12 months) of the dual antiplatelet therapy
(13). However, data on whether adjuvant long-term medical
therapy unevenly affected safety results in the 2 arms were
not provided in the present report.
Uneven randomization schemes (3:1 in this study) led to
unstable outcome measure estimates in the smaller arm (i.e.,
SES group). This increases the risk of a play of chance in this
arm, especially regarding the analysis of rare clinical endpoints.
In the EXCELLENT trial, randomization was stratified for
the presence of diabetes mellitus and long lesions. An interac-
tion was detected in the diabetic cohort that showed a
significantly larger late loss after EES, although this angio-
graphic finding did not translate into diverging clinical end-
points. As discussed, a play of chance cannot be excluded
considering the small diabetic cohort receiving SES. Actually,
this small patient subset had a surprisingly low angiographic
late loss (paradoxically lower than that seen in nondiabetic
patients treated with SES), further preventing a satisfactory
interpretation of this finding. Interestingly, in patients with
diabetes mellitus, previous studies failed to demonstrate the
superiority of EES over PES (3,4) whereas SES remain more
effective than PES in this cohort (14).
EES versus SES randomized trials in perspective. SES
provided a breakthrough in the prevention of restenosis.
Second-generation DES were designed to improve long-term
safety with similar—or even greater—antirestenosis efficacy
than first-generation devices. Accordingly, direct comparisons
of EES with SES remain of major interest to fully elucidate the
potential advantages of novel DES (2). Indeed, SES appear to
be the best possible first-generation DES to be used as a
comparator and ideally suited for benchmark purposes (9).
To date, the final results of 8 randomized studies comparing
head-to-head EES with SES are available (10,15–21). These
studies are heterogeneous regarding: 1) the type of enrolled
patients/lesions (unselected in 4 trials; focused in patients with
diabetes mellitus, 1 trial; large vessels, 1 trial; bifurcations, 1
trial; or acute myocardial infarction, 1 trial); 2) primary end-
points (5 clinical outcomes, 3 angiographic surrogates [1 acute,
2 late]); 3) requirement of late angiography (3 trials); and
4) time of clinical follow-up (from 9 months to 2 years)
(10,15–21). Furthermore, a third arm (different from EES vs.
SES) was included in 2 studies, and 3 trials selected uneven
(different from 1:1) randomization schemes. Finally, clopi-
dogrel duration was also variable (from 6 months to 1 year),
and slight variations in event definitions should be noted. Of
these, 3 studies have been already published (10,15,16), and
final data of 5 trials have been presented as official “late-
breaking clinical trials” at major cardiovascular meetings
(17–21). With these considerations in mind, the available data
may be polled together in a new meta-analysis (Fig. 1). None
of these 8 trials demonstrated superiority of EES over SES in
combined or individual endpoints. The results of this meta-
analysis, totaling 11,351 patients, suggest that EES and SES
provide similar efficacy and safety outcome measures. No
heterogeneity across trials was detected in relation to any event.
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Random-effects meta-analysis of the 8 randomized clinical trials comparing everolimus-eluting stents (EES) with sirolimus-eluting stents (SES) with final data available
(BASKET-PROVE, EXCELLENT, SEA-SIDE, ISAR-TEST-4, SORT-OUT-4, ESSENCE-DIABETES, X-AMI, and RESET) (10,15–21). Forest-plot representation of risk ratios: the size
of the blue squares is related to the powered weight of each individual trial, while red diamonds represent the overall effects. The horizontal axis has a logarithmic
scale. CI  confidence interval; I-TVR  ischemia-driven target vessel revascularization (2 studies reported only total target vessel revascularization); MACE  major
adverse cardiovascular events (death, myocardial infarction, and ischemia-driven target vessel revascularization [with individual event definitions slightly variable among
trials]); MI  myocardial infarction; ST  definitive or probable stent thrombosis (Academic Research Consortium criteria).
11
1
1
1
1
1
1
1
1
2
2
1858 Alfonso and Fernandez JACC Vol. 58, No. 18, 2011
Randomized Comparisons of Limus-Eluting Stents October 25, 2011:1855–8There were, however, clear efficacy and safety “signals” favoring
EES. These would require definitive confirmation in addi-
tional studies with longer clinical follow-up. If present, how-
ever, it remains questionable whether they will be considered as
“clinically relevant” from a practical perspective.
Final remarks. Head-to-head randomized comparisons of
different DES are required to substantiate superior results and
potential changes in clinical practice. Park et al. (10) should be
commended for their interesting, well-conducted study, and
for enlightening our understanding of DES evolution. Many
of these trials, however, represent a premature “photo finish” of
the ongoing “Star Wars.” Ironically, manufacturing of the
time-honored SES used in all these studies has been recently
halted. It is clear that in our “galaxy,” scientific reasons are not
the only gravitational forces. This piece may serve as a farewell
tribute to this still-unbeaten first-generation SES.
Pushing the envelope provides new answers but also begets
new questions. We need to keep on working to translate basic
science discoveries from bench to bedside. Clinical “failures”
should stimulate the reverse process, revisiting bench sources to
come back to the clinical arena with novel solutions. The
clinical and angiographic long-term results currently obtained
with DES are, simply, superb. Nevertheless, scientific hum-
bleness is always more rewarding than narcissism. Every single
patient presenting to us with a DES failure (restenosis and,
especially, thrombosis) should stimulate our passion to keep
spinning the wheel of knowledge. We should never be scared
of flying too high.
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